Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-BLVRB Antibody (2Y112) is a Rabbit antibody targeting BLVRB. Anti-BLVRB Antibody (2Y112) can be used in WB,ELISA,IP.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
100 μL | $269 | 7-10 days |
Description | Anti-BLVRB Antibody (2Y112) is a Rabbit antibody targeting BLVRB. Anti-BLVRB Antibody (2Y112) can be used in WB,ELISA,IP. |
Alias | SDR43U1, HEL-S-10, FLR, BVRB, biliverdin reductase B |
Ig Type | Monoclonal Rabbit IgG |
Clone | 2Y112 |
Reactivity | Human |
Verified Activity | 1. Anti-BLVRB rabbit monoclonal antibody at 1:500 dilution. -Lane A: Hela Whole Cell Lysate. -Lane B: HepG2 Whole Cell Lysate. -Lane C: K562 Whole Cell lysate. -Lysates/proteins at 30 μg per lane. -Secondary -Goat Anti-Rabbit IgG H&L (Dylight800) at 1/10000 dilution. -Developed using the Odyssey technique. -Performed under reducing conditions. -Predicted band size:22 kDa. -Observed band size:22 kDa. 2. BLVRB was immunoprecipitated using: -Lane A:0.5 mg Hela Whole Cell Lysate. -Lane B:0.5 mg HepG2 Whole Cell Lysate. -Lane C:0.5 mg K562 Whole Cell Lysate. -Lane D:0.5 mg Caco-2 Whole Cell Lysate. -2 µL anti-BLVRB rabbit monoclonal antibody and 15 μl of 50 % Protein G agarose. -Primary antibody: -Anti-BLVRB rabbit monoclonal antibody, at 1:100 dilution. -Secondary antibody: -Dylight 800-labeled antibody to rabbit IgG (H+L), at 1:5000 dilution. -Developed using the odyssey technique. -Performed under reducing conditions. -Predicted band size: 22 kDa. -Observed band size: 22 kDa |
Application | WB,ELISA,IP |
Recommended Dose | WB: 1:500-1:2000; ELISA: 1:5000-1:10000; IP: 1-4 μL/mg of lysate |
Antibody Type | Monoclonal |
Host Species | Rabbit |
Construction | This antibody was obtained from a rabbit immunized with purified, recombinant Human BLVRB / biliverdin reductase B (rh BLVRB / biliverdin reductase B; TMPY-02519; P30043; Ala2-Gln206). |
Purification | Protein A |
Appearance | Liquid |
Formulation | 0.2 μm filtered solution in PBS |
Research Background | Biliverdin reductase (hBVR) is a serine/threonine kinase that catalyzes reduction of the heme oxygenase (HO) activity product, biliverdin, to bilirubin. BVR consists of an N-terminal dinucleotide-binding domain (Rossmann-fold) and a C-terminal domain that contains a six-stranded β-sheet that is flanked on one face by several α-helices. The C-terminal and N-terminal domains interact extensively, forming the active site cleft at their interface. Biliverdin reductase (BVR) catalyzes the last step in heme degradation by reducing the γ-methene bridge of the open tetrapyrrole, biliverdin IXα, to bilirubin with the concomitant oxidation of a β-nicotinamide adenine dinucleotide (NADH) or β-nicotinamide adenine dinucleotide phosphate (NADPH) cofactor. It is now recognized that human BVR (hBVR) is a dual-specificity kinase (Ser / Thr and Tyr) upstream activator of the insulin/insulin growth factor-1 (IGF-1) and mitogen-activated protein kinase (MAPK) signaling pathways. Human BVR (hBVR) is essential for MAPK-extracellular signal-regulated kinase (ERK)1/2 (MEK)-eukaryotic-like protein kinase (Elk) signaling and has been identified as the cytoplasm-nuclear heme transporter of ERK1/2 and hematin, the key components of stress-responsive gene expression. |
Conjucates | Unconjugated |
Immunogen | Recombinant Human BLVRB / biliverdin reductase B protein (TMPY-02519) |
Antigen Species | Human |
Stability & Storage | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.